Gilead reported Phase 2 results for emvistegrast (an oral α4β7 inhibitor) in moderate-to-severe ulcerative colitis, reporting symptom elimination with a statistically significant placebo-adjusted clinical remission rate. The company described 200 mg daily dosing for 12 weeks and framed the outcome as potentially best-in-class for an oral option. In the trial, emvistegrast achieved a 23% placebo-adjusted clinical remission rate, exceeding Wall Street expectations cited in the report. Gilead said the results support continued development as it pursues additional inflammatory bowel disease indications. The update reflects how IBD drug development remains intensely competitive, with developers aiming to improve remission depth and sustain outcomes while expanding oral convenience versus infusion-based therapies. For biotech teams, the key near-term question is how emvistegrast’s efficacy and safety profile holds up in larger studies and whether it shows differentiation versus existing α4β7 or downstream pathway competitors.